返回 
加入收藏
司美格鲁肽对比卡格列净治疗二甲双胍控制不佳的2型糖尿病患者的成本-效用分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 司美格鲁肽对比卡格列净治疗二甲双胍控制不佳的2型糖尿病患者的成本-效用分析 |
| TITLE： | Cost-utility analysis of semaglutide versus canagliflozin in patients with type 2 diabetes poorly controlled with metformin |
| 摘要： | 目的 对二甲双胍控制不佳的2型糖尿病（T2DM）患者使用卡格列净或司美格鲁肽治疗的长期经济性进行评价。方法从我国卫生体系角度出发，构建Markov模型，基于SUSTAIN8研究数据模拟我国T2DM患者在二甲双胍基础上联用卡格列净或司美格鲁肽治疗30年的长期成本和效用，并以2024年我国人均国内生产总值（GDP）的1倍作为意愿支付（WTP）阈值计算增量成本-效果比（ICER）和增量净货币收益（INMB）。通过单因素敏感性分析、概率敏感性分析以及情境分析确认基础分析结论的稳定性。结果与卡格列净+二甲双胍方案相比，司美格鲁肽+二甲双胍方案的ICER为260485.67元/质量调整生命年（QALY），大于本研究设定的WTP阈值（95749元/QALY），INMB为－61576.24元，卡格列净+二甲双胍方案更具经济性优势。司美格鲁肽+二甲双胍方案组糖尿病无并发症治疗成本对INMB的影响最大，但参数在选定范围内的变动不会驱动结果发生逆转。随着WTP阈值的增加，司美格鲁肽+二甲双胍方案在经济性上的可接受概率呈上升趋势。在当前WTP阈值下，司美格鲁肽的年成本需下降42.95%，司美格鲁肽+二甲双胍方案才能成为更具经济性优势的方案。结论从中国卫生体系角度出发，对于单用二甲双胍血糖控制不佳的T2DM患者，卡格列净+二甲双胍方案相较于司美格鲁肽+二甲双胍方案更具经济性优势。 |
| ABSTRACT： | OBJECTIVE To evaluate the long-term cost-effectiveness of canagliflozin or semaglutide in patients with type 2 diabetes mellitus（T2DM）poorly controlled with metformin. METHODS Based on the perspective of China’s health system， a Markov model was used to calculate the long-term costs and utilities of canagliflozin or semaglutide combined with metformin for T2DM patients in China for 30 years based on the data from SUSTAIN 8 study. The incremental cost-effectiveness ratio（ICER） and incremental net monetary benefit （INMB） were calculated using one time the 2024 per capita gross domestic product（GDP） as the willingness-to-pay（WTP） threshold. One-way sensitivity analysis， probability sensitivity analysis and scenario analysis were conducted to confirm the stability of the conclusions. RESULTS Compared with canagliflozin + metformin， ICER of semaglutide combined with metformin was 260 485.67 yuan/quality-adjusted life year （QALY），which was higher than the WTP threshold set in this study （95 749 yuan/QALY），and the corresponding INMB was －61 576.24 yuan，indicating that the canagliflozin + metformin regimen was more cost-effective. The cost of diabetes without complications treatment in the semaglutide + metformin group had the greatest influence on INMB，but changes in parameters within the selected range did not drive decision reversal. With the increasing of WTP threshold，the economic acceptability of semaglutide + metformin regimen increased. Under the current WTP threshold，the annual cost of semaglutide should be reduced by 42.95% to make the semaglutide + metformin regimen more cost- effective. CONCLUSIONS From the perspective of China’s health system， canagliflozin + metformin is more cost-effective than semaglutide + metformin for T2DM patients yueru. with poor glycemic control with metformin alone. |
| 期刊： | 2025年第36卷第09期 |
| 作者： | 徐跃洳；王钰博；潘慧敏；单慧亭；陈迹；杨建华 |
| AUTHORS： | XU Yueru，WANG Yubo，PAN Huimin，SHAN Huiting，CHEN Ji，YANG Jianhua |
| 关键字： | 司美格鲁肽；卡格列净；二甲双胍；2型糖尿病；血糖控制不佳；Markov模型；药物经济学；队列模拟 |
| KEYWORDS： | semaglutide； canagliflozin； metformin； type |
| 阅读数： | 11 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
